News & Events about Hh L Acquisition Co Class A.
Abstracts demonstrating XNA technologys improvements to assay sensitivity across different technology platforms and support for use in companion diagnostics (CDx) assay developmentAdditional abstracts to further support XNA technologys potential for use in minimal residual disease (MRD) monitoring ...
Globe Newswire
4 months ago
PLEASANTON, Calif., Jan. 12, 2023 (GLOBE NEWSWIRE) -- DiaCarta, Ltd. (DiaCarta), a precision molecular diagnostics company, today announced thatthe U.S. Food and Drug Administration (FDA) granted Emergency Use Authorization (EUA) for its QuantiVirusTM MPXV test, which is a PCR test for the ...
Globe Newswire
5 months ago
DiaCarta Starts to Receive Samples for Oncuria Bladder Cancer Test at its CLIA Lab PLEASANTON, Calif. and LOS ANGELES, Jan. 05, 2023 (GLOBE NEWSWIRE) -- DiaCarta, Ltd. (DiaCarta), a precision molecular diagnostics company, and Nonagen Bioscience Corporation (Nonagen), a cancer diagnostics company, ...
Business Wire
7 months ago
DiaCarta, Ltd. (DiaCarta or the Company), a precision molecular diagnostics company and developer of novel oncology and infectious disease tests, and HH&L Acquisition Co. (NYSE: HHLA.U, HHLA, HHLA WS) (HH&L), a publicly traded special purpose acquisition company (SPAC), today...
Qube Research & Technologies Ltd lifted its stake in HH&L Acquisition Co. (NYSE:HHLA Get Rating) by 805.8% during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 234,459 shares of the companys stock after buying an additional 208,574...